undamentalytics Newsletter
Sign in

Kymera Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Kymera Therapeutics, Inc. had total assets of $1.74bn, total liabilities of $163m and shareholders' equity of $1.58bn. It held $357m in cash against $0 of debt: net cash of $357m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents76314868110120357373
Receivables———01500—
Total current assets93302451419405510871999
Total assets1174876066035769781,7431,767
Accounts payable344476412
Deferred revenue (current)239362353814230
Total current liabilities35111937186688390
Total debt00000000
Total liabilities82203146113181142163153
Shareholders' equity−742844604903958361,5801,615
Non-controlling interests and other (assets − liabilities − equity)109———————
Net debt (negative = net cash)−76−31−48−68−110−120−357−373
Shares outstanding——52m55m56m65m81m85m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KYMR vs XNCRKYMR vs SEPNAGIO vs KYMR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kymera Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kymera Therapeutics, Inc.